Header Logo

Connection

MICHAEL R MIGDEN to Retreatment

Back to Details
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Retreatment.
MICHAEL R MIGDEN
Connection Strength
0.035
Retreatment
  1. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na?ve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2082-2091.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.